Johnson & Johnson (JNJ)

$254.93 +0.52 (0.20%)
Market Cap 613.10B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 23.60
Forward PE 21.93
Profit Margin 28.46%
Debt to Equity Ratio 0.44
Volume 7,362,300
Avg Vol 8,396,452
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 18%
Beta 0.24
Analysts Strong Sell
Price Target $273.67

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
dewmoore
dewmoore Aug. 5 at 11:38 AM
When Big Pharma spends billions on drugs that fail to give patients long-term life, $SLS looks insanely valuable. 🔥 $JNJ is hunting for a $20B revenue gap to hit $50B in oncology by 2030, pouring cash into AML drugs with POOR durability (4.4 mo post-relapse survival). Meanwhile, $SLS dominates where Big Pharma fails: • SLS009: 8.9 mo MOS (vs 2.5 mo historical) • GPS: 13.5+ mo MOS (vs 6 mo standard) Meanwhile, the buyout puzzle pieces click: Leadership Lineup: Tom Cavanagh (leading $JNJ acquisitions) overlapped directly with Katherine Bach Kalin at Celgene. Inside Bet: Katherine sits on the $SLS Board and bought 63,400 shares out of pocket (104,400 total). $$$ Muscle: With massive cash flow and pristine balance sheets, $JNJ can easily finance a multi-billion dollar buyout. Big Pharma's desperation for real survival data makes $SLS an ultimate prize. 🚀 Buyout Boys Ranking: #1 $JNJ #2 $LLY #3 $MRK (runner up $PFE ) Gilead FAILED $5B Drug: Our floor is $25 per share
1 · Reply
Londonplay
Londonplay Aug. 5 at 10:59 AM
$SLS more likely $JNJ
1 · Reply
DominickKinslow1074
DominickKinslow1074 Aug. 5 at 9:23 AM
$GIS $IEP $JNJ $KO $KR General Mills generates dependable cash flow, Icahn Enterprises remains value-oriented, Johnson & Johnson provides defensive healthcare exposure, Coca-Cola leads global beverages, and Kroger expands digital grocery services.
0 · Reply
FrederickAllen970
FrederickAllen970 Aug. 5 at 9:14 AM
$JNJ $MA $CSCO $INTC $BAC Johnson & Johnson offers defensive healthcare exposure, Mastercard leads payment networks, Cisco expands AI networking, Intel continues its manufacturing turnaround, and Bank of America benefits from higher financial activity.
0 · Reply
DennisKubie952
DennisKubie952 Aug. 5 at 8:17 AM
$GIS $IEP $JNJ $KO $KR General Mills generates dependable cash flow, Icahn Enterprises remains value-oriented, Johnson & Johnson provides defensive healthcare exposure, Coca-Cola leads global beverages, and Kroger expands digital grocery services.
0 · Reply
MarieLeonard935
MarieLeonard935 Aug. 5 at 7:26 AM
$JNJ $GTBIF $RIG $NASA $PHAT Johnson & Johnson provides defensive healthcare exposure, Green Thumb Industries leads U.S. cannabis operations, Transocean benefits from offshore drilling demand, NASA-related investments remain speculative, and Phathom advances gastrointestinal therapies.
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Aug. 4 at 11:47 PM
$JNJ $PFE $SLS Part 3. No Open Market purchases after J.P Morgan 1x1 meetings with $JNJ and $PFE. Cluster purchases came before J.P Morgan 1x1 because all insiders and independent BOD have MNPI. Negotiations have been going on under strict NDA/MOU since December 2025. Now you all understand why we voted 3 million shares in favor of Dr. Stergiou stock award. We want Dr. Stergiou aligned with Comon Retail folks here that have been longs for a very long time. Dr. Stergiou has 1,875,000 reasons to Negotiate the best BO! ✌️🙏❤️‍🩹
1 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Aug. 4 at 11:36 PM
$JNJ $PFE $SLS Part 2. Katherine Bach is A deep immunotherapy expert. Previously at Celgene (sold to BMS for $74 BILLION) Experienced in AML, hematology, cell therapies Very familiar with survival data patterns & regulatory signals. Katherine Kalin's stock purchase is especially bullish because she's not just any board member, she led M&A strategy at Celgene and BOD at $JNJ. 👇 ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Aug. 4 at 11:30 PM
$JNJ $SLS $PFE So JNJ wants to close the deal in September 2026 after GPS Regal Pivotal Registrational CURATIVE Phase 3 data hits in August 2026 and Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September takes over. Yes Katherine Bach Sellas independent BOD has very strong history with Mr. Cavanaugh as they facilitated one of the biggest Pharmaceutical BO of all time Bristol Myers Squibb (BMY) officially acquired Celgene on November 20, 2019, in a massive cash-and-stock deal valued at roughly $74 billion. The merger created a biopharma giant by adding blockbuster drugs like Revlimid to Bristol Myers Squibb's extensive oncology and immunology portfolio.Key details of the acquisition include:The Deal Terms: Celgene shareholders received $50 in cash and 1.0 share of Bristol Myers Squibb common stock for each share they held, representing an enterprise value of $90 billion at the time of the agreement. let’s what Dr. Bourla $PFE does! ✌️🙏❤️‍🩹
2 · Reply
Bomber18
Bomber18 Aug. 4 at 10:20 PM
$JNJ $SLS might I add that in 11/25, Katherine Bach Kaline purchased 63,400 shares of SLS out of pocket and is still holding them today. Very interesting connection here to say the least….
0 · Reply
Latest News on JNJ
Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference

Aug 4, 2026, 4:05 PM EDT - 15 hours ago

Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference

Johnson & Johnson announces Taubert to retire as EVP, Worldwide Chairman

2026-08-04T12:50:51.000Z - 22 hours ago

Johnson & Johnson announces Taubert to retire as EVP, Worldwide Chairman

JNJ

Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

Aug 4, 2026, 8:45 AM EDT - 23 hours ago

Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

Johnson & Johnson Transcript: Investor update

Aug 3, 2026, 8:00 AM EDT - 1 day ago

Johnson & Johnson Transcript: Investor update

Johnson & Johnson price target raised to $282 from $272 at Wells Fargo

2026-08-03T11:00:29.000Z - 2 days ago

Johnson & Johnson price target raised to $282 from $272 at Wells Fargo

JNJ

Johnson & Johnson removed from US Conviction List at Goldman Sachs

2026-08-03T09:35:43.000Z - 2 days ago

Johnson & Johnson removed from US Conviction List at Goldman Sachs

JNJ

Inside J&J's Lab to Create a Simpler Robotic Surgery Device

Aug 2, 2026, 8:00 AM EDT - 2 days ago

Inside J&J's Lab to Create a Simpler Robotic Surgery Device

Johnson & Johnson’s head & neck cancer candidate granted FDA Priority Review

2026-07-30T12:35:46.000Z - 5 days ago

Johnson & Johnson’s head & neck cancer candidate granted FDA Priority Review

JNJ

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

Jul 30, 2026, 8:30 AM EDT - 5 days ago

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines

Jul 29, 2026, 6:13 PM EDT - 6 days ago

Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

Jul 29, 2026, 5:42 PM EDT - 6 days ago

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

Johnson & Johnson sees Firefly, Sail Biomedicines dilute FY27 EPS by $1.36

2026-07-29T21:40:31.000Z - 6 days ago

Johnson & Johnson sees Firefly, Sail Biomedicines dilute FY27 EPS by $1.36

JNJ

Johnson & Johnson lowers 2026 profit forecast

Jul 29, 2026, 5:38 PM EDT - 6 days ago

Johnson & Johnson lowers 2026 profit forecast

Johnson & Johnson cuts FY26 EPS view to $10.86-$11.01, consensus $11.68

2026-07-29T21:35:31.000Z - 6 days ago

Johnson & Johnson cuts FY26 EPS view to $10.86-$11.01, consensus $11.68

JNJ

Johnson & Johnson affirms FY26 revenue view of $100.8B-$101.4B

2026-07-29T21:35:19.000Z - 6 days ago

Johnson & Johnson affirms FY26 revenue view of $100.8B-$101.4B

JNJ

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Jul 29, 2026, 5:28 PM EDT - 6 days ago

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Explainer: Can J&J finally put the talc litigation behind it?

Jul 29, 2026, 12:01 PM EDT - 6 days ago

Explainer: Can J&J finally put the talc litigation behind it?

Johnson & Johnson price target raised to $300 from $290 at Argus

2026-07-29T13:31:13.000Z - 6 days ago

Johnson & Johnson price target raised to $300 from $290 at Argus

JNJ

Johnson & Johnson offers $5.5 billion to settle remaining lawsuits over talc products linked to cancer

Jul 28, 2026, 4:31 PM EDT - 7 days ago

Johnson & Johnson offers $5.5 billion to settle remaining lawsuits over talc products linked to cancer

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

Jul 28, 2026, 12:26 PM EDT - 7 days ago

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuit

Jul 28, 2026, 1:03 AM EDT - 8 days ago

Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuit

J&J offers $5.5bn to settle baby powder lawsuits

Jul 28, 2026, 12:31 AM EDT - 8 days ago

J&J offers $5.5bn to settle baby powder lawsuits

Johnson & Johnson Agrees to Pay $5.5 Billion to Settle Talc Lawsuits

Jul 27, 2026, 9:29 PM EDT - 8 days ago

Johnson & Johnson Agrees to Pay $5.5 Billion to Settle Talc Lawsuits

Johnson & Johnson announces $5.5 billion settlement of talc lawsuits

Jul 27, 2026, 6:47 PM EDT - 8 days ago

Johnson & Johnson announces $5.5 billion settlement of talc lawsuits

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

Jul 27, 2026, 6:31 PM EDT - 8 days ago

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

Robert Kiyosaki sees a brutal depression ahead: 3 stocks that may protect portfolios

Jul 27, 2026, 5:45 AM EDT - 9 days ago

Robert Kiyosaki sees a brutal depression ahead: 3 stocks that may protect portfolios

NEM WMT

Johnson & Johnson’s multiple myeloma therapy shows efficacy in Phase 3 trial

2026-07-23T12:35:56.000Z - 12 days ago

Johnson & Johnson’s multiple myeloma therapy shows efficacy in Phase 3 trial

JNJ

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

Jul 23, 2026, 8:30 AM EDT - 12 days ago

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

US judge casts doubt on 69,000 cases alleging J&J talc caused cancer

Jul 22, 2026, 4:33 PM EDT - 13 days ago

US judge casts doubt on 69,000 cases alleging J&J talc caused cancer

Johnson & Johnson's robotic surgery device gets US FDA marketing authorization

Jul 22, 2026, 7:21 AM EDT - 14 days ago

Johnson & Johnson's robotic surgery device gets US FDA marketing authorization

Johnson & Johnson receives FDA Marketing Authorization in U.S. for OTTAVA

2026-07-22T11:05:32.000Z - 14 days ago

Johnson & Johnson receives FDA Marketing Authorization in U.S. for OTTAVA

JNJ

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

Jul 22, 2026, 7:00 AM EDT - 14 days ago

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

Jim Cramer says this old-school investing concept still wins — even in the AI boom

Jul 21, 2026, 6:30 PM EDT - 14 days ago

Jim Cramer says this old-school investing concept still wins — even in the AI boom

BNY CVS GS MMM WFC

Johnson & Johnson upgraded to Buy at Freedom Broker after strong quarter

2026-07-16T17:30:35.000Z - 19 days ago

Johnson & Johnson upgraded to Buy at Freedom Broker after strong quarter

JNJ

Johnson & Johnson upgraded to Buy from Hold at Freedom Broker

2026-07-16T17:25:12.000Z - 19 days ago

Johnson & Johnson upgraded to Buy from Hold at Freedom Broker

JNJ

Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

Jul 16, 2026, 8:11 AM EDT - 19 days ago

Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

DePuy Synthes Acquires Expanding Innovations™

Jul 16, 2026, 8:00 AM EDT - 19 days ago

DePuy Synthes Acquires Expanding Innovations™

J&J Leverages AI and Robots to Target $100 Billion in Annual Revenue

Jul 15, 2026, 12:09 PM EDT - 20 days ago

J&J Leverages AI and Robots to Target $100 Billion in Annual Revenue

Johnson & Johnson Earnings Call Transcript: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 20 days ago

Johnson & Johnson Earnings Call Transcript: Q2 2026

Johnson & Johnson Slides: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 20 days ago

Johnson & Johnson Slides: Q2 2026

Johnson & Johnson Earnings release: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 20 days ago

Johnson & Johnson Earnings release: Q2 2026

Johnson & Johnson Quarterly report: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 20 days ago

Johnson & Johnson Quarterly report: Q2 2026

ASML, Intel, Johnson & Johnson, and More Stocks That Explain Today's Market

Jul 15, 2026, 7:27 AM EDT - 21 days ago

ASML, Intel, Johnson & Johnson, and More Stocks That Explain Today's Market

ASML INTC

Johnson & Johnson Hikes Guidance, Stock Falls

Jul 15, 2026, 6:35 AM EDT - 21 days ago

Johnson & Johnson Hikes Guidance, Stock Falls

Johnson & Johnson Bumps Up Guidance as Sales Rise

Jul 15, 2026, 6:33 AM EDT - 21 days ago

Johnson & Johnson Bumps Up Guidance as Sales Rise

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

Jul 15, 2026, 6:25 AM EDT - 21 days ago

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Jul 15, 2026, 6:23 AM EDT - 21 days ago

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

Jul 15, 2026, 6:20 AM EDT - 21 days ago

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

The Big 3: UNH, KO, JNJ

Jul 9, 2026, 1:00 PM EDT - 26 days ago

The Big 3: UNH, KO, JNJ

KO UNH

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jul 8, 2026, 7:45 AM EDT - 4 weeks ago

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jim Cramer says these are the 5 stocks to buy during this market rotation

Jul 6, 2026, 6:29 PM EDT - 4 weeks ago

Jim Cramer says these are the 5 stocks to buy during this market rotation

PEP SBUX STZ TJX

Healthcare stocks have become a haven for investors ditching tech

Jun 26, 2026, 2:39 PM EDT - 5 weeks ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE LLY MRNA SNY XBI

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Jun 26, 2026, 12:35 PM EDT - 5 weeks ago

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jun 25, 2026, 5:00 AM EDT - 5 weeks ago

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

Jun 15, 2026, 6:00 AM EDT - 7 weeks ago

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 13, 2026, 6:41 AM EDT - 7 weeks ago

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 13, 2026, 6:33 AM EDT - 7 weeks ago

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Jun 11, 2026, 7:45 AM EDT - 7 weeks ago

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

Jun 11, 2026, 7:14 AM EDT - 7 weeks ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS AMGN GILD IBB IHE KYMR

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Jun 11, 2026, 2:03 AM EDT - 7 weeks ago

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Jun 10, 2026, 11:22 AM EDT - 7 weeks ago

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Jun 10, 2026, 6:20 AM EDT - 2 months ago

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 10:00 AM EDT - 2 months ago

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

Jun 9, 2026, 9:20 AM EDT - 2 months ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN LLY MRK NVO PFE

Johnson & Johnson to Buy Firefly Bio for $1 Billion

Jun 8, 2026, 9:01 AM EDT - 2 months ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion

Johnson & Johnson to buy Firefly Bio for $1 billion

Jun 8, 2026, 8:08 AM EDT - 2 months ago

Johnson & Johnson to buy Firefly Bio for $1 billion

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

J&J beats lawsuit alleging that talc caused three women's cancer

Jun 5, 2026, 6:24 PM EDT - 2 months ago

J&J beats lawsuit alleging that talc caused three women's cancer

dewmoore
dewmoore Aug. 5 at 11:38 AM
When Big Pharma spends billions on drugs that fail to give patients long-term life, $SLS looks insanely valuable. 🔥 $JNJ is hunting for a $20B revenue gap to hit $50B in oncology by 2030, pouring cash into AML drugs with POOR durability (4.4 mo post-relapse survival). Meanwhile, $SLS dominates where Big Pharma fails: • SLS009: 8.9 mo MOS (vs 2.5 mo historical) • GPS: 13.5+ mo MOS (vs 6 mo standard) Meanwhile, the buyout puzzle pieces click: Leadership Lineup: Tom Cavanagh (leading $JNJ acquisitions) overlapped directly with Katherine Bach Kalin at Celgene. Inside Bet: Katherine sits on the $SLS Board and bought 63,400 shares out of pocket (104,400 total). $$$ Muscle: With massive cash flow and pristine balance sheets, $JNJ can easily finance a multi-billion dollar buyout. Big Pharma's desperation for real survival data makes $SLS an ultimate prize. 🚀 Buyout Boys Ranking: #1 $JNJ #2 $LLY #3 $MRK (runner up $PFE ) Gilead FAILED $5B Drug: Our floor is $25 per share
1 · Reply
Londonplay
Londonplay Aug. 5 at 10:59 AM
$SLS more likely $JNJ
1 · Reply
DominickKinslow1074
DominickKinslow1074 Aug. 5 at 9:23 AM
$GIS $IEP $JNJ $KO $KR General Mills generates dependable cash flow, Icahn Enterprises remains value-oriented, Johnson & Johnson provides defensive healthcare exposure, Coca-Cola leads global beverages, and Kroger expands digital grocery services.
0 · Reply
FrederickAllen970
FrederickAllen970 Aug. 5 at 9:14 AM
$JNJ $MA $CSCO $INTC $BAC Johnson & Johnson offers defensive healthcare exposure, Mastercard leads payment networks, Cisco expands AI networking, Intel continues its manufacturing turnaround, and Bank of America benefits from higher financial activity.
0 · Reply
DennisKubie952
DennisKubie952 Aug. 5 at 8:17 AM
$GIS $IEP $JNJ $KO $KR General Mills generates dependable cash flow, Icahn Enterprises remains value-oriented, Johnson & Johnson provides defensive healthcare exposure, Coca-Cola leads global beverages, and Kroger expands digital grocery services.
0 · Reply
MarieLeonard935
MarieLeonard935 Aug. 5 at 7:26 AM
$JNJ $GTBIF $RIG $NASA $PHAT Johnson & Johnson provides defensive healthcare exposure, Green Thumb Industries leads U.S. cannabis operations, Transocean benefits from offshore drilling demand, NASA-related investments remain speculative, and Phathom advances gastrointestinal therapies.
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Aug. 4 at 11:47 PM
$JNJ $PFE $SLS Part 3. No Open Market purchases after J.P Morgan 1x1 meetings with $JNJ and $PFE. Cluster purchases came before J.P Morgan 1x1 because all insiders and independent BOD have MNPI. Negotiations have been going on under strict NDA/MOU since December 2025. Now you all understand why we voted 3 million shares in favor of Dr. Stergiou stock award. We want Dr. Stergiou aligned with Comon Retail folks here that have been longs for a very long time. Dr. Stergiou has 1,875,000 reasons to Negotiate the best BO! ✌️🙏❤️‍🩹
1 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Aug. 4 at 11:36 PM
$JNJ $PFE $SLS Part 2. Katherine Bach is A deep immunotherapy expert. Previously at Celgene (sold to BMS for $74 BILLION) Experienced in AML, hematology, cell therapies Very familiar with survival data patterns & regulatory signals. Katherine Kalin's stock purchase is especially bullish because she's not just any board member, she led M&A strategy at Celgene and BOD at $JNJ. 👇 ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Aug. 4 at 11:30 PM
$JNJ $SLS $PFE So JNJ wants to close the deal in September 2026 after GPS Regal Pivotal Registrational CURATIVE Phase 3 data hits in August 2026 and Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September takes over. Yes Katherine Bach Sellas independent BOD has very strong history with Mr. Cavanaugh as they facilitated one of the biggest Pharmaceutical BO of all time Bristol Myers Squibb (BMY) officially acquired Celgene on November 20, 2019, in a massive cash-and-stock deal valued at roughly $74 billion. The merger created a biopharma giant by adding blockbuster drugs like Revlimid to Bristol Myers Squibb's extensive oncology and immunology portfolio.Key details of the acquisition include:The Deal Terms: Celgene shareholders received $50 in cash and 1.0 share of Bristol Myers Squibb common stock for each share they held, representing an enterprise value of $90 billion at the time of the agreement. let’s what Dr. Bourla $PFE does! ✌️🙏❤️‍🩹
2 · Reply
Bomber18
Bomber18 Aug. 4 at 10:20 PM
$JNJ $SLS might I add that in 11/25, Katherine Bach Kaline purchased 63,400 shares of SLS out of pocket and is still holding them today. Very interesting connection here to say the least….
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Aug. 4 at 9:33 PM
$JNJ $SLS 🤐 Sowy Mr. Dew my Inglis not too good but you say in earlier post that Michael Frascello, MBA © • J&J Product Director Post liking and commenting on Dr. Stergiou Post is Den yparchei típota na deite edó(Nothing to see here) but than you post EVP of J&J Tom Cavanaugh worked alongside Sellas Katherine Bach Kalin Sellas Current Independent BOD in Celgene BO Bristol Myers Squibb (BMY) officially acquired Celgene on November 20, 2019, in a massive cash-and-stock deal valued at roughly $74 billion. The merger created a biopharma giant by adding blockbuster drugs like Revlimid to Bristol Myers Squibb's extensive oncology and immunology portfolio.Key details of the acquisition include:The Deal Terms: Celgene shareholders received $50 in cash and 1.0 share of Bristol Myers Squibb common stock for each share they held, representing an enterprise value of $90 billion at the time of the agreement. Sellas Independent BOD is only BOD with open market purchase before J&J 1x1 at J.P Morgan.🤣
0 · Reply
Martyg724
Martyg724 Aug. 4 at 9:20 PM
$SLS $JNJ $SLS $JNJ There are so many valid arguments as to who is the most likely pharma master to take over. It's clearly going to be the one who wants to be the MASTER for next 12-20 years, AT ALL COST - ALL IN !!!!!!!
0 · Reply
dewmoore
dewmoore Aug. 4 at 9:09 PM
$SLS Family Tree check... 👀 Tom Cavanaugh was just named EVP & Worldwide Chairman of Innovative Medicine at $JNJ Guess who sits on the Board of Directors at $SLS ??? Katherine Bach Kalin. Guess where they both spent years overlapping as high-level executives in global strategy and product development from 2012 to 2017? CELGENE Celgene: BOTH Tom and Katherine overlapped as senior executives in global strategy/product development (2012–2017). $JNJ : Katherine spent nearly a decade at J&J in leadership/business development (2002–2011). You really think these two haven't grabbed a coffee or drinks in the past few days to catch up? 😂☕️🍻 Connect the dots! https://ca.finance.yahoo.com/news/johnson-johnson-executive-vice-president-124500987.html
6 · Reply
Gebinator
Gebinator Aug. 4 at 8:53 PM
$SLS And -- is $JNJ promoting key staff for good strategic reasons? https://ca.finance.yahoo.com/news/johnson-johnson-executive-vice-president-124500987.html
0 · Reply
dewmoore
dewmoore Aug. 4 at 8:52 PM
$SLS Great to see a $JNJ Product Director showing respect to Dr. Stergiou and $SLS, but let’s not read too much into it. Product Directors manage brand lifecycles, not secret corporate buyouts under strict NDAs. It’s great validation, but if J&J actually had an active NDA in play, corporate legal wouldn't let anyone give public high-fives on social media or anywhere else including LinkedIn It’s fun to dream, but stay grounded for now.... from me to you I still say my top 3 buyout boys are : #1 $MRK #2 $JNJ #3 $LLY
3 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Aug. 4 at 8:19 PM
$SLS $JNJ🤐 Den yparchei típota na deite edó. 👇 ✌️🙏❤️‍🩹
0 · Reply
RarelyRight
RarelyRight Aug. 4 at 7:54 PM
$DFTX $JNJ $CMPS $ATAI JNJ has to buy one of these. Spravato is going to get destroyed by psychedelics.
2 · Reply
Johnmtnb2018
Johnmtnb2018 Aug. 4 at 7:47 PM
$SLS $JNJ Looks like JNJ is the winner !
2 · Reply
Mountainmannn
Mountainmannn Aug. 4 at 7:41 PM
$ABUS I'd love to see $JNJ come in here buy us for 11 billion in stock...
3 · Reply
OmarKingW
OmarKingW Aug. 4 at 6:43 PM
$IBRX $JNJ $MRK VERY BULLISH FOR LONG INVESTORS: Things still moving ahead cleanly. Growth continues with more than 50m revenue and the only thing that hurt the numbers is 230.4m (.22 per share) spending vs 92.6m (.09 per share)from prior year) NON Cash accounting charges. Street expected the loss to be .08-.09 per share. The explanation is very clear from the company to me n it’s a cost of rapid growth for the year activating convertible notes, warrants, and related derivative liabilities. The widening seems concerning but it’s not in reality because we did grow rapidly from $1.80 all the way to $12. THE STORY BEEING TOLD IS NOTHING CHANGES GROWTH AND EXPANSION CONTINUES RESULTING INTO SOME OF THE NON CASH SPIKE) THESE WILL BE MANGED GOING FORWARD AND WILL REDUSE SIGNIFICANTLY GOING FORWARD. THINK: LONG AND STRONG 💪🏼
0 · Reply
Diefreeandsell
Diefreeandsell Aug. 4 at 6:19 PM
$IBRX $JNJ $MRK VOLUME wow it's really great today. No catastrophe! 14.15mil shares, +14% compared to typical volume of 12.41mil by 2:09 pm ET. Typical daily volume is 19.4mil shares over the past 6 months. Co's commercial execution has significantly altered its financial risk profile over the past few quarters. It just reported its Q2 2026 financials, delivering $50.7 million in net product revenue from ANKTIVA in USA only. This is up 92% year-over-year and marks the eighth consecutive quarter of sequential revenue growth since launch, you're disappointed? WTF Bottom Line: The current $357M+ cash pile, paired with an ANKTIVA commercial run rate now exceeding $200 million annually, provides ImmunityBio with a stable runway through late 2027. Late 2027-WTF!!! This comfortably covers the company past its crucial January 6, 2027 PDUFA date and right up to the anticipated late-2026 BCG-naïve FDA submission window. You think it won't succeed, think again!
1 · Reply
H_hi
H_hi Aug. 4 at 5:31 PM
$NVO we need to merge with $JNJ asap!
0 · Reply